You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Biogen’s inherited eye disease gene therapy misses primary endpoint

A gene therapy developed by Biogen for the rare inherited eye disease X-linked retinitis pigmentosa (XLRP) has failed to meet the primary endpoint in a Phase II/III study.